In the brains of AD patients, aberrant CpG methylation of APP occurs, possibly contributing to the aberrant gene expression of APP. Targeted DNA methylation editing can be performed by fusing Tet1 or Dnmt3a with dCas9 [15]. This evidence concerns the gene DNMT3A and Alzheimer disease.